Search Results

You are looking at 151 - 160 of 473 items for :

  • Refine by Access: All x
Clear All
Full access

R. Lor Randall and William Gowski

. Philadelphia, PA : Lippincott-Raven ; 1996 . 17 Colyer RA Sallay P Buckwalter K . MRI assessment of chondroid matrix tumors . In: Limb Salvage: Current Trends–Proceedings of the 7th International Symposium. Singapore: International Symposium of

Full access

Nishant Patel, Adam C. Yopp, and Amit G. Singal

Most patients presented initially with an abnormal imaging study, with 219 (48%) presenting with abnormal abdominal ultrasound and 149 (33%) presenting with a mass on CT or MRI. AFP level was elevated in 135 patients (30%) including 67 whose

Full access

Bishal Gyawali and Saroj Niraula

Bayesian theorem. These rates are continually estimated and updated based on the decrease in tumor volume as assessed by MRI scans. Decrease in tumor volume on MRI scans is yet to be validated as a surrogate for achieving pCR. Thus, in I-SPY 2, a correlate

Full access

brain MRI.” ➤ 7th bullet was added: “Baseline CRP and serum ferritin.” • Post-CAR T-Cell Infusion: ➤ 1st bullet was revised: “Hospitalization or extremely close outpatient monitoring at centers with transplant or prior outpatient CAR T

Full access

patients with cancer by outlining all imaging procedures recommended in the NCCN Guidelines, including radiographs, CT scans, MRI, functional nuclear medicine imaging (PET, SPECT), and ultrasound. NCCN is recognized by Centers for Medicare & Medicaid

Full access

on disease stage and histology. All imaging procedures recommended in the NCCN Guidelines, including radiographs, CT scans, MRI, functional nuclear medicine imaging (PET, SPECT), and ultrasound, are included within NCCN Imaging AUC. NCCN Imaging AUC

Full access

extraction on drug bioavailability. Secondary Objectives: Assess by RECIST clinical responses signals in a broad array of solid tumors. Evaluate whether dynamic contrast enhanced MRI to determine the degree of vascular permeability and PET scan to

Full access

-weighted MRI for analysis of in vivo tumor cellularity. Patients are followed up for 5 years after completion of study therapy. Primary Outcome Measures: Determine maximum tolerated dose of vorinostat given in combination with capecitabine and RT

Full access

expression and genome-wide copy number using gene, microRNA, and CGH arrays Assess the use of dynamic contrast-enhanced MRI in STS evaluation. Contacts: William Tap, MD • 212-639-5720 Gary Schwartz, MD • 212-639-8324 ClinicalTrials

Full access

Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson

imaging modality for diagnosing RCC and evaluating the extent and stage of disease. MDCT has been associated with 91% accuracy for tumor staging and up to 100% accuracy for assessment of venous tumor invasion. 2 With improvements in CT technology, MRI